Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors

Olaratumab is a monoclonal antibody that specifically binds to platelet‐derived growth factor receptor alpha (PDGFRα) and blocks receptor activation. We conducted a phase 1 trial to evaluate the safety of olaratumab and determine a recommended dose in combination with three different chemotherapy re...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Med
Autori principali: Mascarenhas, Leo, Ogawa, Chitose, Laetsch, Theodore W., Weigel, Brenda J., Bishop, Michael W., Krystal, Julie, Borinstein, Scott C., Slotkin, Emily K., Muscal, Jodi A., Hingorani, Pooja, Levy, Donna E., Mo, Gary, Shahir, Ashwin, Wright, Jennifer, DuBois, Steven G.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2021
Soggetti:
Clinical Cancer Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7897905/
https://ncbi.nlm.nih.gov/pubmed/33474828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3658
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi